Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, shares some insights into the challenges associated with myeloma treatment in the age of novel immunotherapies. Prof. Lonial first comments on the variety of immunotherapies that exist for patients with myeloma, including bispecific antibodies, CAR-T cells, and antibody-drug conjugates (ADCs). Prof. Lonial then explains the need to decide which agents to combine and when to use different classes of agents to provide patients with the best treatment approach. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

свернуть